amylin glp-1 dual agonist Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease Media Centre | EASD

served on scientific advisory panels and/or speakers bureaus and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi

However, SGLT2 inhibitors have stronger evidence for renal and heart failure outcomes and are generally preferred in adults with type 2 diabetes and chronic kidney disease or heart failure, unless contraindicated or not tolerated

8 Cost The high cost of these medications is a barrier to many patients continuing them, with US list prices or $12,000-16,000 per year, and over $6500 a year at maximum discount

By activating glucagon-like peptide-1 (GLP-1) receptors, retatrutide stimulates insulin secretion from pancreatic beta cells and inhibits glucagon release

Practitioners are encouraged to follow existing guidelines and engage in continuing education to better understand the evolving therapeutic landscape

This makes them a dual-action therapy targeting both metabolic and inflammatory pathways